Overview

A Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AMG 592 in Healthy Participants

Status:
Completed
Trial end date:
2017-07-28
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety, tolerability and immunogenicity profile of single and multiple dose administrations of AMG 592 in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen